Provided by Tiger Trade Technology Pte. Ltd.

Arbutus Biopharma

5.19
-0.0150-0.29%
Volume:2.74M
Turnover:14.18M
Market Cap:1.02B
PE:6.57
High:5.26
Open:5.25
Low:5.13
Close:5.20
52wk High:5.45
52wk Low:3.50
Shares:196.94M
Float Shares:123.00M
Volume Ratio:0.62
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7896
EPS(LYR):-0.1748
ROE:89.58%
ROA:48.84%
PB:3.95
PE(LYR):-29.65

Loading ...

Arbutus Q1 FY26 net income turns to USD 169.7 million; revenue rises to USD 179.1 million

Reuters
·
May 13

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data

Dow Jones
·
May 13

Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins

Dow Jones
·
May 13

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B

Reuters
·
Apr 15

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
Apr 15

Arbutus Biopharma announces annual general and special shareholders meeting

Reuters
·
Apr 15

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

TIPRANKS
·
Apr 07

Arbutus Biopharma Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 25

Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate

Benzinga Earnings
·
Mar 23

Earnings Flash (ABUS) Arbutus Biopharma Posts 2025 Loss $0.17 a Share, vs. FactSet Est of $0.19 Loss

MT Newswires Live
·
Mar 23

Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment

Reuters
·
Mar 23

Arbutus Biopharma FY 2025 net loss was USD 34 million, revenue rose 128% to USD 14 million

Reuters
·
Mar 23

Press Release: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 23

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 05

Moderna litigation outcome ‘favorable,’ but leaves some risk, says BofA

TIPRANKS
·
Mar 04

BUZZ-Street View: Wall Street views Moderna's legal settlement as clearing a major overhang

Reuters
·
Mar 04

Moderna Stock Rallies. This Big Risk Just Got Eliminated. -- Barrons.com

Dow Jones
·
Mar 04

24H | Moderna and TotalEnergies Jump 8%; GitLab Drops 8%; Arbutus Biopharma Sinks 12%

Tiger Newspress
·
Mar 04